Brief: Curanex Pharmaceuticals Advancing Phyto-N Toward A Planned Investigational New Drug Submission To FDA For Ulcerative Colitis In Q4 2026
14/05/2026 14:05
Curanex Pharmaceuticals Inc CURX.O: CURANEX PHARMACEUTICALS: ADVANCING PHYTO-N TOWARD A PLANNED INVESTIGATIONAL NEW DRUG SUBMISSION TO FDA FOR ULCERATIVE COLITIS IN Q4 2026 Source text: ID:nGNX1yxLvf Further company coverage: CURX.O
Recent news on Curanex Pharmaceuticals
See all newsBrief: Curanex Pharmaceuticals - Securities Class Action Filed Against Curanex Pharmaceuticals And Underwriters On July 23, 2026 - SEC Filing
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Curanex Pharmaceuticals Advancing Phyto-N Toward A Planned Investigational New Drug Submission To FDA For Ulcerative Colitis In Q4 2026